First Time Loading...
S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.26 CNY 1.13% Market Closed
Updated: Apr 28, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Shenzhen Salubris Pharmaceuticals Co Ltd

Wall Street analysts forecast Shenzhen Salubris Pharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shenzhen Salubris Pharmaceuticals Co Ltd is 37.74 CNY with a low forecast of 33.33 CNY and a high forecast of 43.05 CNY.

Lowest Forecast
Wall Street Target
33.33 CNY
7% Upside
Average Forecast
Wall Street Target
37.74 CNY
21% Upside
Highest Forecast
Wall Street Target
43.05 CNY
38% Upside
Lowest
Price Target
33.33 CNY
7% Upside
Average
Price Target
37.74 CNY
21% Upside
Highest
Price Target
43.05 CNY
38% Upside
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors:
Price Targets
REC
Recordati Industria Chimica e Farmaceutica SpA
6% Upside
460
Sihuan Pharmaceutical Holdings Group Ltd
389% Upside
ROG
Roche Holding AG
28% Upside
STAR
Strides Pharma Science Ltd
3% Downside
REC
Recordati Industria Chimica e Farmaceutica SpA
6% Upside
460
Sihuan Pharmaceutical Holdings Group Ltd
389% Upside
ROG
Roche Holding AG
28% Upside
STAR
Strides Pharma Science Ltd
3% Downside
FULC
Fulcrum Therapeutics Inc
89% Upside
002001
Zhejiang Nhu Co Ltd
11% Upside
W
300871
Wuhan Hvsen Biotechnology Co Ltd
27% Upside
LLY
Eli Lilly and Co
15% Upside

Revenue
Forecast

Revenue Estimate
Shenzhen Salubris Pharmaceuticals Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's revenue is 0%. The projected CAGR for the next 3 years is 18%.

0%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Shenzhen Salubris Pharmaceuticals Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's operating income is -10%. The projected CAGR for the next 2 years is 14%.

-10%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Shenzhen Salubris Pharmaceuticals Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's net income is -9%. The projected CAGR for the next 3 years is 16%.

-9%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's stock price target?
Price Target
37.74 CNY

According to Wall Street analysts, the average 1-year price target for Shenzhen Salubris Pharmaceuticals Co Ltd is 37.74 CNY with a low forecast of 33.33 CNY and a high forecast of 43.05 CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's revenue is 0%. The projected CAGR for the next 3 years is 18%.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's operating income is -10%. The projected CAGR for the next 2 years is 14%.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Shenzhen Salubris Pharmaceuticals Co Ltd's net income is -9%. The projected CAGR for the next 3 years is 16%.

ALPHA SPREAD
Join more than 132,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.